A Case of Advanced Hepatocellular Carcinoma with Partial Response after Continuous Ramucirumab Treatment beyond Radiological Progression

scientific article published on 01 January 2020

A Case of Advanced Hepatocellular Carcinoma with Partial Response after Continuous Ramucirumab Treatment beyond Radiological Progression is …
instance of (P31):
case reportQ2782326
scholarly articleQ13442814

External links are
P356DOI10.1159/000506331
P932PMC publication ID7184828
P698PubMed publication ID32355493

P2093author name stringShin Sasaki
Hajime Imamura
Hiroki Ureshino
Yoshiyuki Wada
Yuko Takami
Hideki Saitsu
Tomoki Ryu
P2860cites workRamucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trialQ91147767
Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trialsQ91723916
Sorafenib in advanced hepatocellular carcinomaQ27861075
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialQ29547903
Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinomaQ34207858
The Efficacy of Continued Sorafenib Treatment after Radiologic Confirmation of Progressive Disease in Patients with Advanced Hepatocellular Carcinoma.Q35888783
Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR groupQ37046852
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trialQ38785510
On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study.Q38933901
Efficacy of sorafenib beyond first progression in patients with metastatic hepatocellular carcinomaQ43454599
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trialQ50046367
Cabozantinib in Patients with Advanced and Progressing Hepatocellular CarcinomaQ56373211
P433issue1
P921main subjecthepatocellular carcinomaQ1148337
P304page(s)379-384
P577publication date2020-01-01
P1433published inCase reports in oncologyQ27722654
P1476titleA Case of Advanced Hepatocellular Carcinoma with Partial Response after Continuous Ramucirumab Treatment beyond Radiological Progression
P478volume13

Search more.